Company: COPL-UN
Filing Date: 2025-04-01
Form Type: S-1/A
Source: 0001829126-25-002247
Chunk: 16

Company: Copley Acquisition Corp
Filing Date: 2025-04-01
Form: S-1/A
Chunk 16
---
 our sponsor acquired
the founder shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of this
offering, assuming no value is ascribed to the warrants included in the units. Further, the Class A ordinary shares issuable in connection
with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights
of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one-for-one basis upon conversion.
See the section titled “Risk Factors — Risks Relating to our Sponsor and Management Team — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline” on page 73. In addition, the cashless exercise of the placement warrants included in the placement
units purchased by our sponsor at the closing of this offering would increase the dilution to our public shareholders. Further, the conversion
of any working capital loans or extension loans into private placement units (which would be identical to the placement units sold in
the private placement), as well as the cashless exercise of the placement warrants that are issued as part of such units, would further
increase the dilution to our public shareholders.

The following table illustrates
the difference between the public offering price per unit and our net tangible book value per share (NTBV), as adjusted to give effect
to this offering and assuming the redemption of our public shares at varying levels and the exercise in full and no exercise of the over-allotment
option. See section entitled “Dilution” on page 109 for more information.

| As of December 31, 2024                         |                                      |     |                         |      |     |                |      |     |                         |      |     |                |      |     |                          |      |     |                |      |     |                          |       |   |     |                |       |
|:------------------------------------------------|-------------------------------------:|:----|:------------------------|-----:|:----|:---------------|-----:|:----|:------------------------|-----:|:----|:---------------|-----:|:----|:-------------------------|